Description: Cadila Healthcare Limited engages in the research, development, production, marketing, and distribution of pharmaceutical products in India, the United States, and internationally. It offers finished dosage human formulations comprising generics, branded generics, and specialty formulations, including biosimilars and vaccines; active pharmaceutical ingredients; animal healthcare products; and consumer wellness products. The company offers products in the therapeutic areas of pain management, neurology, dermatology, rare diseases, specialty oncology, gastroenterology, and liver diseases. It also provides consumer wellness products, such as Sugar Free and Sugarlite; Complan; EverYuth, a range of skincare products; Nycil, a prickly heat powder; Glucon-D glucose powder; Sampriti Ghee; Nutralite; and various other products. In addition, the company is developing drugs in the areas of oncology, autoimmune disease, nephrology, ophthalmology, inflammation, rheumatology, hepatology, infectious disease, etc. Further, it offers animal healthcare products for various therapeutic areas, such as anti-bacterial, NSAIDs, anti-mastitis, tonics, and poultry vaccines. The company also engages in the retail pharmacy, and manpower supply and administration activities. Cadila Healthcare Limited was founded in 1952 and is based in Ahmedabad, India.
Home Page: www.zyduscadila.com
Zydus Corporate Park
Ahmedabad,
382481
India
Phone:
91 79 7180 000
Officers
| Name | Title |
|---|---|
| Dr. Sharvil Pankajbhai Patel | MD & Exec. Director |
| Mr. Nitin D. Parekh | Chief Financial Officer |
| Dr. Ganesh Narayan Nayak | COO & Exec. Director |
| Mr. Dhaval N. Soni | Company Sec. & Compliance Officer |
| Vishal Gor | Vice Pres of Corp. Fin. at Zydus Cadila |
Exchange: BSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 23.2558 |
|---|---|
| Trailing PE: | 25.7618 |
| Price-to-Book MRQ: | 3.711 |
| Price-to-Sales TTM: | 2.9817 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 25000 |